Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Factors predicting response of Crohn's disease to infliximab

Smoking has a strong adverse effect on response to infliximab, in patients with Crohn's disease, reports a team of researchers at this week's BSG meeting in Birmingham, England.

News image

fiogf49gjkf04

Up to 75% of patients given infliximab for Crohn’s disease (CD) will respond.

A number of parameters predicting response have been proposed, but none have been reproduced in an independent cohort.

In this study, researchers aimed to identify markers of response in patients receiving infliximab at the Western General Hospital, Edinburgh, Scotland.

The research team assessed 74 CD patients (42 female, mean age 34 years).

They prospectively collected full clinical data and blood was taken for the inflammatory markers ASCA and ANCA.

Of the 74 patients, 11 had ileal disease, 25 colonic disease and 10 had recurrence following ilesotomy.

There is a trend towards better response rates in patients with colonic disease.
BSG

Overall, 16 patients had received azathioprine for > 3 months and 5 had received methotrexate.

The team gave the 60 patients with luminal disease single infusions of infliximab (5mg/kg), while 3 infusions were given to the 14 patients with fistulating disease.

They assessed disease activity using the Harvey-Bradshaw index. They defined a response as a reduction of 4 or more points, or a 50% reduction in draining fistula.

The research team determined that patients who smoked more than 5 cigarettes per day for over 6 months were less likely to respond to infliximab than those who did not (52% versus 83%).

The team also found that patients on azathioprine for longer than 3 months at infusion were more likely to respond (94% versus 67%).

In addition, they identified a trend towards better response rates in those with colonic disease, and worse response rates in those with perianal disease.

The team did not find that age at diagnosis, previous surgery, sex, pre-infusion disease activity, CRP, and ASCA/ANCA status influenced response rates in this cohort.

Dr Arnott’s team concluded, “Smoking has a strong adverse effect on response rates to infliximab”.

“Furthermore, patients established on azathioprine for greater than 3 months had greater response rates.”

“Every effort should be made to discourage CD patients from smoking.”

"92% of patients established on azathioprine prior to treatment responded: this has clear implications for clinical practice."

BSG
26 March 2003

Go to top of page Email this page Email this page to a colleague

 26 February 2018 
Metabolic effects of new therapies of NASH
 26 February 2018 
Hepatocellular carcinoma risk in Hep B
 26 February 2018 
Novel targets for hepatocellular carcinoma
 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us